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Abstract
Background: The purpose of this study was to evaluate the change of food intake after different dosages of
botulinum toxin A (BTX) injection in the animal model. Additionally, the dimensional and histological change at
14 days after BTX injection was also evaluated.
Methods: The comparative study was performed using the BTX injection model in rats (n = 5 for each group).
Group 1 was the saline-injected group. Group 2 was the 5-unit BTX-injection group to each masseter muscle. Group
3 was the 10-unit BTX-injection group to each masseter muscle. Food intake rates and body weight were checked
daily before and after BTX injection until 10 days. All animals were sacrificed at 14 days after BTX injection, and the
specimens underwent hematoxylin and eosin stain and immunohistochemical staining for myosin type II (MYH2).
Results: The recovery of food intake in groups 2 and 3 decreased significantly compared with group 1 from day 2
to day 7 and day 9 after injection (p < 0.05). The BTX-treated masseter muscles were significantly smaller than
those in group 1 (p = 0.015). The immunohistochemical findings demonstrated that the expression of MYH2 was
significantly higher in group 3 compared to groups 1 and 2 (p < 0.001).
Conclusions: BTX injection to the masseter muscle in rats demonstrated short food-intake-rate reduction with
recovery until 10 days after injection. The thickness of the masseter muscle and MYH2 expression were significantly
changed according to the injected dose of BTX.
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Background
Botulinum toxin A (BTX), a toxin produced by Clostridium
botulinum, binds to snail protein in the presynaptic cho-
linergic nerve and inhibits the acetylcholine release [1]. As
the neurotransmitter of the motor nerve is acetylcholine,
BTX can be used for intentional skeletal muscle weaken-
ing [2]. BTX can be used to decrease the hyperactivity of
the masseter and the temporal muscles for reducing pain-
ful conditions [2]. Myofascial pain is described as a muscle
hyperactivity involving facial pain related to temporoman-
dibular disorders [3]. Tension headaches and neck pain
are usually caused by masticatory muscle hyperactivity [4].
Secretion of the salivary gland and sweat gland is also
controlled by the cholinergic nerve [5]. Accordingly, BTX
has been widely used in the dental field. BTX is used for
the treatment of temporomandibular disorders [2], sialor-
rhea [5], post-traumatic open bite [6], and masseteric
muscle hypertrophy [7, 8].
To achieve optimal results, optimal dosage of BTX in-
jection should be important. For the treatment of the
masseter muscle hypertrophy, 25 to 30 U of BTX has
been generally given for each side [7, 9]. The maximum
bite force is reduced after injection of BTX into the mas-
seter muscle [10]. Complications of BTX injection into
the masseter muscle, such as a temporary change in the
bite force, have been reported [7, 8].
There have been several reports to investigate the
effect of BTX injection into the masseter muscle in the
animal model [11–14]. The injection of BTX immedi-
ately reduces the masseter muscle activity measured by
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electromyogram [12]. BTX changes the component of
muscle fiber and morphology of the mandible at 1 month
after injection [13, 14]. However, early changes of muscle
fiber component have not been studied. Post-traumatic
open bite is corrected within a couple of days after BTX
injection [6]. Some patients showed temporary muscle
weakness immediately after BTX injection [7, 8]. Thus,
early change after BTX injection on the masseter muscle
is important to understand the clinical application of
BTX.
The purpose of this study was to evaluate the change
of food intake after different dosages of BTX injection in
the animal model. Additionally, dimensional and histo-
logical change at 14 days after BTX injection was also
evaluated.
Methods
Animals and experimental design
Male Wistar rats aged 18 weeks were purchased from
Samtako (Seoul, Korea). They were housed individually
in controlled temperature (20–22 °C) and hygrometry
(around 40 %) in a 12-h light:12-h darkness cycle. They
had free access to water. During the adaptation period
(first week), all rats were fed ad libitum with a control
semi-synthetic diet (4 % lipids from soya vegetal oil,
74 % carbohydrates from sucrose and cornstarch, and
14 % proteins from casein, supplemented with standard
vitamins and mineral mix), following classical recom-
mendations. All diets were prepared within Gangneung-
Wonju National University facilities. All groups were
maintained ad libitum for 7 days receiving a diet similar
to the adaptation diet with measuring of daily spontan-
eous intake (26.1 ± 4.1 g/day, n = 15). At the end of the
normal diet period, rats (20 weeks old) were sepa-
rated: the control group received a saline injection
into both masseter muscles (group 1, n = 5), and the
others were separated in two groups for BTX injec-
tion study (n = 5 per group). These two groups were
assessed in order to compare the dose-dependent
effect of BTX injection on physiological parameters in
two animal groups receiving re-feeding diets. All re-
feeding diets were the same to the ad libitum control
period. In order to measure food intake, all groups
were individually housed. Group 1 was the saline-
injected group. Group 2 was the 5-unit BTX-injection
group to each masseter muscle. Group 3 was the 10-
unit BTX-injection group to each masseter muscle.
The recovery of food intake was measured until
10 days after the injection. All animals were sacrificed
at 14 days after the injection for the histological ana-
lysis. All procedures were conducted according to the
guidelines of laboratory animal care and were ap-
proved by the Gangneung-Wonju National University
for animal research (GWNU-2015-24).
Histomorphometric evaluation
The samples were harvested, decalcified in 5 % nitric
acid for 5 days, and dehydrated in ethyl alcohol and
xylene. After separation of the calvarial bones, the
samples were embedded in paraffin blocks. The paraffin
blocks were sliced into sections that were then stained
with hematoxylin and eosin. The section with the occlu-
sal plane area was selected.
The staining procedure for hematoxylin and eosin
staining was as follows. First, de-wax and hydrate
paraffin sections. The slide was stained in hematoxylin
for 5 min. Overstained sections can easily be differenti-
ated by agitating for a second in acid-alcohol then wash-
ing in tap water for 5 min. The slides were immersed in
eosin for 30 s and then washed in running tap water for
1 min. The slides were dehydrated and cleared in xylene.
Digital images of the selected sections were captured
with a digital camera (DP-73; Olympus, Tokyo, Japan).
The images were analyzed by Sigma Scan pro (SPSS,
Chicago, IL). The thickness of the masseter muscle was
measured from the perpendicular line to the mandibular
ramus.
Immunohistochemical determination of lysozyme and
myosin type II in rat masseter muscle
To determine the level of expression of myosin type II
(MYH2), immunohistochemical staining was performed
using anti-myosin type II antibodies (Santa Cruz Biotech,
Santa Cruz, CA, USA). Paraffin-embedded tissues from
rat masseter muscles were prepared. For antigen retrieval,
sections were incubated in trypsin for 7 min at 37 °C. The
primary antibody dilutions were as follows: MYH2, 1:50.
The immunohistochemical procedures were performed as
described in a previous publication [15]. The negative
controls were sections stained without primary antibodies.
Stained sections were examined in an Olympus BX51
(Olympus, Tokyo, Japan) microscope. To quantify the
immunohistochemical reaction intensity, the positive
intensity MYH2 staining in 10 random fields at ×200
magnification in the masseter muscle was evaluated by
computer-assisted image analysis after image transform-
ation to grayscale. The staining intensity was expressed
as the mean intensity value (0, no stain; 255, highest
stain). The samples were not counterstained so that the
absorbance would be solely attributable to the product
of the immunohistochemical reaction.
Statistical analysis
SPSS for Windows ver. 19 (IBM Co., Armonk, NY, USA)
were used for statistical analysis. The differences among
groups were evaluated by ANOVA. For post hoc tests,
Bonferroni’s method was used. The statistically signifi-
cant level was set as p < 0.05.
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Results
There was no initial difference between the BTX and
saline solution groups in any parameter, including body
weight and the amount of food consumption during
24 h. Figure 1 illustrates the relative amount of food
consumption during the 24 h compared to before the
injection. The relative amount of food intake in rats
treated with BTX (5–10 U) decreased significantly
compared with the saline group from day 2 to day 7 and
day 9 after injection (p < 0.05). In the post hoc test, both
5- and 10-U BTX treatments resulted in significantly
lower values compared with the saline-treated control
group from day 2 to day 6 (p < 0.05). However, only the
10-U BTX treatment resulted in significantly lower
values compared with the saline-treated control group at
day 7 and day 9 (p = 0.031 and 0.049, respectively).
There was no significant difference in body weight
between the observation points (data not shown).
The BTX-treated masseter muscles were significantly
smaller than the saline-solution-injected masseter mus-
cles, as shown in Figs. 2 and 3. The thickness of the
masseter muscle was 5.76 ± 1.28 mm, 4.66 ± 0.68 mm,
and 3.65 ± 0.81 mm for the saline, 5-U, and 10-U BTX
treatments, respectively (Fig. 2; p = 0.015). The post hoc
test revealed differences between the group treated with
10 U BTX and the group treated with saline (control)
resulting in significantly lower values (p = 0.013). In the
histological view, the degenerative change of muscle
fibers was prominent in the 10-U BTX-treated group.
Inter-fiber spaces were lost in the 10-U BTX-treated
group. Mild degenerative change was also noticed in the
5-U BTX-treated group (Fig. 3).
The immunohistochemical findings demonstrated
that the expression of MYH2 was much higher in the
10-U BTX-treated group compared to the saline group
(Fig. 4). The mean intensity of MYH2 was 86.38 ± 8.66,
101.72 ± 12.41, and 144.51 ± 5.68 for the saline, 5-U, and
10-U BTX treatments, respectively (Fig. 4; p < 0.001). The
post hoc test revealed differences between the groups
treated with 10 U BTX, resulting in significantly higher
values compared with the saline-treated control and the
5-U BTX-treated group (p < 0.001).
Discussion
Recovery after BTX injection
In this study, the recovery in food intake after BTX in-
jection was taken approximately 10 days after injection
(Fig. 1). When BTX is injected into the unilateral mas-
seter muscle of an adult rabbit, the relative bite force is
reduced over 85 % in 3 weeks after injection [16]. Thus,
10 days might be a relatively fast recovery. After BTX in-
jection of the unilateral masseter muscle, rabbits still
masticate at the same rates and chew on both sides [16].
At 12 weeks after unilateral injection, bite force has
returned to pre-injection levels but the BTX-injected
masseter muscle volume is still smaller than the contra-
lateral muscle [16]. This might have been due to the
compensatory hyperfunction of the temporalis muscle to
adjust to the masticatory function [17]. In this study, the
other masticatory muscles were intact except for the
masseter muscle. Thus, early recovery of food intake rate
might be due to the compensatory function of the other
masticatory muscles.
The clinical literature indicates that maximal atrophy
of the masseter of human is observed about 2 months
after BTX injection and is sometimes persistent until 1
to 2 years [18, 19]. However, voluntary bite force is sub-
jectively normal within 8 days after BTX injection in one
report [20]. Patients report only brief periods of prob-
lems with chewing after BTX injection and the return of
normal function after a short time [21]. Our results
demonstrated similar results with previous publications
(Fig. 1).
Fig. 1 The relative amount of food consumption during 24 h compared
to before the injection. The recovery of food intake in rats treated with
BTX (5–10 U) decreased significantly compared with the saline group
from day 2 to day 7 and day 9 after injection (asterisk, p < 0.05)
Fig. 2 The thickness of the masseter muscle. The thickness of the
masseter muscle in rats treated with BTX (5–10 U) was decreased
significantly compared with the saline group at day 14 after
injection (asterisk, p = 0.015)
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Muscle and bone changes after BTX injection
The dosage of BTX expected to cause muscle paralysis is
20–30 U for rodents [22]; therefore, 5 and 10 U were
used in this experiment. Injections of BTX decrease the
force of masseter muscle contractions and decrease
tension on the periosteum [23]. The BTX-treated mas-
seter muscles were significantly smaller than the saline-
solution-injected masseter muscles, as shown in Fig. 2.
The masseter muscle may be involved in maintaining
mandibular bone volume through changes in bone me-
tabolism [22]. Accordingly, bony deposition decreases
and a morphological change are induced [24]. A reduced
cortical bone thickness of the mandibular ramus in our
study (Fig. 3) was also consistent with the research of
previous publications [25, 26]. The diminished forces
cause the remodeling process of bone growth, which cir-
cumferentially reduces the cortical bone thickness.
When BTX is used on the limb muscle, bone loss is ob-
served in the tibia and distal femur [27, 28].
MYH change after BTX injection
MYH is found in all eukaryotic cells, where it provides
the motor function [29]. There are several types of
MYH, and they can be classified by their contraction
speed as fast type and slow type [29]. MYH2 is fast type
[30]. Masticatory muscle fibers can adapt to stress by
changing their myosin composition, and they are found
after orthognathic surgery of patients with malocclusions
[31, 32]. The patients having mandibular asymmetry
are associated with a significant increase of MYH2
[33]. In addition, MYH2 occupancy is increased in
deep bites [34].
It was shown that intramuscular BTX application
induces direct and significant alterations of the fiber
composition [35]. Just like BTX injection, chronic
denervation is followed by changes of the fiber type
composition and MYH content in rat muscles [36, 37].
Endurance muscle training induced by sagittal advance-
ment of the mandible induces an increase of MYH1 in
pigs [38]. MYH2 is increased in the masseter muscle
after BTX injection [39]. In our study, MYH2 was
significantly increased in the masseter muscle after BTX
injection and its increasing was BTX dose dependent
(Fig. 4). Unlike BTX injection, sleep deprivation is
associated with significantly decreased MYH2 in the
masseter muscle in rats [40]. Though our study indi-
cated that BTX injection could increase MYH2 occu-
pancy in the masseter muscle, because human masseter
Fig. 3 Histological view. a The saline-treated group, b 5-U BTX-treated group, c 10-U BTX-treated group. Interestingly, the thickness of the mandibular
ramus (asterisk) was changed after BTX injection. Degenerative change was also shown in both the 5- and 10-U BTX-treated groups (hematoxylin and
eosin stain, original magnification ×20)
Fig. 4 Immunohistological view. a The saline-treated group, b 5-U BTX-treated group, c 10-U BTX-treated group. The immunohistochemical findings
demonstrated that the expression of MYH2 was much higher in the 10-U BTX-treated group compared to the saline group (original magnification ×100
without counterstain)
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and temporal muscles have also heterogeneous fiber-
type composition, the proportion of MYH2 being gener-
ally smaller [41], there will be needed translational
research in humans.
Conclusions
In conclusion, BTX injection to the masseter muscle in
rats demonstrated a short food-intake-rate reduction
with recovery until 10 days after injection. The thickness
of the masseter muscle and MYH2 expression were
significantly changed according to the injected dose
of BTX.
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